Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial

PURPOSE: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunosuppressive pathway is often upregulated in MCC, and advanced metastatic MCC frequently responds to PD...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Oncol
Main Authors: Topalian, Suzanne L., Bhatia, Shailender, Amin, Asim, Kudchadkar, Ragini R., Sharfman, William H., Lebbé, Celeste, Delord, Jean-Pierre, Dunn, Lara A., Shinohara, Michi M., Kulikauskas, Rima, Chung, Christine H., Martens, Uwe M., Ferris, Robert L., Stein, Julie E., Engle, Elizabeth L., Devriese, Lot A., Lao, Christopher D., Gu, Junchen, Li, Bin, Chen, Tian, Barrows, Adam, Horvath, Andrea, Taube, Janis M., Nghiem, Paul
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2020
Teme:
Rapid Communications
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7392746/
https://ncbi.nlm.nih.gov/pubmed/32324435
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00201
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki